
The U.S. Department of Justice Civil Division and the Department of Health and Human Services announced a joint initiative on October 22, 2026. The new Healthcare False Claims Act Self-Disclosure Pilot Program aims to give healthcare businesses a structured pathway to resolve past legal violations by coming forward voluntarily.
According to federal officials, the program focuses government enforcement efforts on entities that refuse to take responsibility. Participating companies must detail all relevant conduct, share documents regarding the violations, and report corrective actions taken to address the issues.
Companies that participate in the pilot program must provide complete records that reflect the nature, terms, and operation of any potential violations under the federal False Claims Act. In addition to describing the misconduct, organizations are required to explain the remedial steps they implemented to fix the underlying problem.
Participants must also make a financial repayment to the government. The repayment terms include a multiplier ranging between 1.25 and 1.6. The exact multiplier applied depends on several factors, including how quickly the company came forward, the scope of the behavior, involvement by senior leaders, financial gain, and whether the organization holds successor liability for misconduct it promptly corrected.
Source: U.S. Department of Justice
Organizations that successfully complete the program requirements receive specific legal benefits. The government offers a coordinated civil release from liability under both the federal False Claims Act and certain administrative authorities managed by HHS.
Federal officials emphasized that voluntary disclosures demonstrate an active commitment to compliance and accountability. Companies willing to take responsibility gain a predictable framework to resolve past actions, allowing them to remain stronger partners in federal healthcare programs.
The pilot program is open for electronic submissions through April 22, 2027. Companies can send their disclosures directly to the Justice Department. Officials noted that late or incomplete submissions will not receive a review.
The current program applies strictly to potential civil violations. Any business seeking to disclose potential criminal conduct related to healthcare must direct those matters to the Justice Department’s National Fraud Enforcement Division under separate existing policies.
For ordinary people, this program serves as an administrative mechanism for federal agencies to recover taxpayer funds and penalize unlawful billing practices in the healthcare sector. While the initiative targets corporate entities rather than individuals, it utilizes whistleblowers and government enforcement resources to root out exploitation within federal healthcare systems.
When dealing with complex corporate compliance policies, federal investigations, or potential legal exposure, consulting a qualified attorney may help companies navigate reporting requirements and negotiate resolutions.
The program provides companies with a clear formula and defined multiplier to calculate repayments, reducing uncertainty in corporate resolutions.
With a firm cutoff date of April 22, 2027, healthcare companies must act quickly to evaluate past conduct and prepare disclosures.
By rewarding voluntary compliance, federal agencies aim to redirect enforcement resources toward companies that refuse to self-report.
Healthcare entities considering self-disclosure should consult an attorney experienced in corporate compliance to review potential liabilities.
| Requirement | Details |
|---|---|
| Participating Agencies | DOJ Civil Division & HHS |
| Financial Repayment Multiplier | 1.25 to 1.6 multiplier |
| Submission Deadline | April 22, 2027 |
| Benefit to Companies | Coordinated civil release from liability |
Source: U.S. Department of Justice
Federal rules apply nationwide, but your options depend on your state and situation. Browse attorneys by practice area, then pick your state.
This article is general information based on U.S. Department of Justice and court or agency records available at publication time. It is not legal advice; laws and deadlines differ by state and by case. Published October 23, 2026.
Source: U.S. Department of Justice
The DOJ's new Fraud Whistleblower Incentive Program will pay $10,000‑$30,000 for tips that lead to criminal charges, focusing on health‑care and federal benefit fraud.
Thousands of consumers who lost money through Walmart wire transfer services are receiving checks totaling more than $9.8 million from the FTC.
The agency now allows Anktiva with BCG for adults whose high‑grade papillary‑only bladder tumors have not responded to BCG, the first such approval.
CVS Pharmacy will pay $315 million to settle DOJ claims it filled dubious opioid prescriptions and sought Medicare reimbursements, and will add new safeguards to monitor prescribing patterns.
The FTC closed its probe after Gildan Activewear and S&S Holdings amended their agreement to let Gildan set prices for any North American distributor, curbing discriminatory pricing.